Hemostatic Effects of A-fact, which is a new hemostatic agent

Background: The use of hemostatic agents is used to stop the bleeding. In medicine, an ideal hemostatic agent should have been stop venous bleeding after being applied to the lesion. This study investigated the in vitro effects of A-Fact a hemostatic parameter. Methods: It has been determined in human plasma at different rates. Hemostatic parameters were determined using routine biochemical methods. For morphological evaluation in full blood, microscopic images of 5%, 10%, 15% and 50% drugs applied to blood samples were taken. Results: A-Fact induced the very fast formation of protein network. Coagulation test was performed on 2/20 dilution. The coagulation factor (II, VII, IX) was studied. The levels of coagulation factors were not affected by A-Fact. Plasma fibrinogen activities, total protein, albumin and globulin levels decreased, in parallel and with the prolonged prothrombin time. And also INR values were increased following the addition of the A-Fact. Conclusion: Our results suggested that the mechanism of A-Fact bleeding stopper has shown the formation of the protein network. These data support that A-Fact may be evaluated as a new hemostatic agent.Background: The use of hemostatic agents is used to stop the bleeding. In medicine, an ideal hemostatic agent should have been stop venous bleeding after being applied to the lesion. This study investigated the in vitro effects of A-Fact a hemostatic parameter. Methods: It has been determined in human plasma at different rates. Hemostatic parameters were determined using routine biochemical methods. For morphological evaluation in full blood, microscopic images of 5%, 10%, 15% and 50% drugs applied to blood samples were taken. Results: A-Fact induced the very fast formation of protein network. Coagulation test was performed on 2/20 dilution. The coagulation factor (II, VII, IX) was studied. The levels of coagulation factors were not affected by A-Fact. Plasma fibrinogen activities, total protein, albumin and globulin levels decreased, in parallel and with the prolonged prothrombin time. And also INR values were increased following the addition of the A-Fact. Conclusion: Our results suggested that the mechanism of A-Fact bleeding stopper has shown the formation of the protein network. These data support that A-Fact may be evaluated as a new hemostatic agent. 

Amaç: Kanamayı durdurmak için hemostatik ajanların kullanılır. Tıpta, ideal bir hemostatik ajan lezyona uygulandıktan sonra venöz kanamayı durdurmalıdır. Bu çalışmada A-Fact’ın hemostatik parametrelerinin invitro etkileri araştırılacaktır. Yöntem: İnsan plazmasında farklı oranlarda belirlenmiştir. Hemostatik parametreler rutin biyokimyasal yöntemler kullanılarak belirlendi. Tam kanda morfolojik değerlendirme için kan örneklerine% 5,% 10,% 15 ve% 50 ilaçların mikroskobik görüntüleri alındı. Bulgular: A-Fact, protein ağının çok hızlı oluşumunu sağladı. Koagülasyon testi 2/20 seyreltme üzerinde yapıldı. Koagülasyon faktörü 2,7 ve 9 çalışıldı ve A-Fact koagülasyon faktörlerini etkilemedi. . Plazma fibrinojen aktivitesi, total protein, albümin ve globulin düzeyleri azalırken buna paralel olarak protrombin zamanı uzadı. Ayrıca, A-Fact eklendikten sonra INR değerleri artırıldı. Sonuç: Sonuçlarımıza göre; A-Fact kanama durdurucunun mekanizması protein ağı oluşumunu gösterdi. Elde edilen veriler A-fact’ı yeni bir hemostatik ajan olarak gösterdi.